Brexpiprazole

Catalog No.S4639 Synonyms: OPC-34712

Brexpiprazole Chemical Structure

Molecular Weight(MW): 433.57

Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors with Ki values of 0.3, 0.12, 0.47, 0.17 and 0.59 nM for D2L, 5-HT1A, 5-HT2A, α1B receptors and α2C receptors respectivey.

Size Price Stock Quantity  
USD 97 In stock
USD 297 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Dopamine Receptor Inhibitors

Biological Activity

Description Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors with Ki values of 0.3, 0.12, 0.47, 0.17 and 0.59 nM for D2L, 5-HT1A, 5-HT2A, α1B receptors and α2C receptors respectivey.
Targets
5-HT1A [1]
(Cell-free assay)
human noradrenergic α1B [1]
(Cell-free assay)
Dopamine D2L [1]
(Cell-free assay)
5-HT2A receptors [1]
(Cell-free assay)
α2C receptors [1]
(Cell-free assay)
0.12 nM(Ki) 0.17 nM(Ki) 0.3 nM(Ki) 0.47 nM(Ki) 0.59 nM(Ki)
In vitro

Brexpiprazole is a potent partial agonist at human 5-hydroxytryptamine (5-HT) 5-HT1A (Ki=0.12 nM) and dopamine D2L (Ki=0.3 nM) receptors, and an antagonist at 5-HT2A receptors (Ki=0.47 nM). It also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2Creceptors (Ki=0.59 nM). Furthermore, this drug displays moderate affinity for human D3, 5-HT2B and 5-HT7 receptors, as well as α1A, and α1D adrenergic receptors. Brexpiprazole potentiated NGF-induced neurite outgrowth in PC12 cells. It could significantly potentiate the effects of fluoxetine (or paroxetine) on neurite outgrowth[1].

In vivo Brexpiprazole is able to ameliorate PCP- 191 induced cognitive deficits in mice, via 5-HT1A receptors[2].

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: PC12 cells
  • Concentrations: 0.001, 0.01, 0.1 or 1.0 μM
  • Incubation Time: 4 days
  • Method: 2.5 ng/ml of NGF(nerve growth factor) is used to study the potentiating effects of brexpiprazole on neurite outgrowth. Twenty-four hours after plating, the medium is replaced with DMEM medium containing 0.5% FBS and 1% penicillin-streptomycin with NGF (2.5 ng/ml), with or without brexpiprazole (0.001, 0.01, 0.1 or 1.0 μM). Four days after incubation with NGF (2.5 ng/ml) with or without drugs, morphometric analysis is performed on digitized images of live cells taken under phase-contrast illumination, with an inverted microscope linked to a camera.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male ICR mice
  • Formulation: 0.5% methylcellulose
  • Dosages: 0.3, 1, or 3 mg/kg/day
  • Administration: oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 24 mg/mL (55.35 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 433.57
Formula

C25H27N3O2S

CAS No. 913611-97-9
Storage powder
in solvent
Synonyms OPC-34712

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03198078 Recruiting Schizophrenia Otsuka Pharmaceutical Development & Commercialization Inc.|H. Lundbeck A/S June 30 2017 Phase 3
NCT03198078 Recruiting Schizophrenia Otsuka Pharmaceutical Development & Commercialization Inc.|H. Lundbeck A/S June 30 2017 Phase 3
NCT03033069 Completed Stress Disorders Post-Traumatic Otsuka Pharmaceutical Development & Commercialization Inc.|H. Lundbeck A/S January 2017 Phase 2
NCT03033069 Completed Stress Disorders Post-Traumatic Otsuka Pharmaceutical Development & Commercialization Inc.|H. Lundbeck A/S January 2017 Phase 2
NCT02875080 Completed Healthy Adult Male Otsuka Pharmaceutical Co. Ltd. September 27 2016 Phase 1
NCT02875080 Completed Healthy Adult Male Otsuka Pharmaceutical Co. Ltd. September 27 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Dopamine Receptor Signaling Pathway Map

Related Dopamine Receptor Products0

Tags: buy Brexpiprazole | Brexpiprazole ic50 | Brexpiprazole price | Brexpiprazole cost | Brexpiprazole solubility dmso | Brexpiprazole purchase | Brexpiprazole manufacturer | Brexpiprazole research buy | Brexpiprazole order | Brexpiprazole mouse | Brexpiprazole chemical structure | Brexpiprazole mw | Brexpiprazole molecular weight | Brexpiprazole datasheet | Brexpiprazole supplier | Brexpiprazole in vitro | Brexpiprazole cell line | Brexpiprazole concentration | Brexpiprazole nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID